Potential Use of ES Cells for Cardiac Tissue Engineering

ES 细胞在心脏组织工程中的潜在用途

基本信息

  • 批准号:
    7339853
  • 负责人:
  • 金额:
    $ 17.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-01-15 至 2009-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This revised application is being submitted in response to the program announcement (PA) "Exploratory/ Developmental (R21) Bioengineering Research Grants (EBRG PA-03-058). Cardiovascular disease is the number one cause of death in the United States. Adult cardiomyocytes do not proliferate and therefore cardiac muscle cannot regenerate when the cells are permanently injured. We have recently isolated several pure populations of cardiomyocytes from murine ES cells which express cardiac specific genes. We propose to use these cells as a renewable source in tissue engineered constructs. To create these constructs, the cells will be mixed with collagen and fibronectin. The constructs will be exposed to multiple mechanical or electrical stimulation regiments using a custom designed device. As the heart develops, gene expression of ventricular cardiomyocytes changes to that of terminally differentiated cardiomyocytes. We are hypothesizing that mechanical load and electrical stimulation will induce our genetically selected cardiomyocytes to become better organized and more highly differentiated. Preliminary data has provided proof of concept for the creation of a construct using either HL-1 cardiomyocytes or the genetically selected ES cells. This data also shows that a mechanical load can be applied to the constructs using the device and that the mechanical load has a direct effect on the morphology of the construct and its cellular components. The proposed research defines a plan that will enable us to optimize the conditions for creating a cardiac tissue engineered construct and to investigate the effect that mechanical load and electrical stimulation has on the differentiation of ES cardiomyocytes. Reverse transcription PCR will be utilized to evaluate the effect that mechanical and electrical stimulation has on cardiac gene expression. The cellular morphology of the construct will be assessed with histology, immunohistochemistry, and transmission electron microscopy. In addition, the mechanical properties of the construct will be tested and compared to normal heart muscle. The significance of this work is that if we are successful in our goals then this methodology could be applied to the use of human ES cells for the therapeutic repair of injured cardiac muscle or the creation of artificial cardiac tissue for surgical repair or as a source of tissue for reconstructive surgery of congenital birth defects.
描述(由申请人提供):本修订申请是为了响应项目公告(PA)“探索/开发(R21)生物工程研究赠款(EBRG PA-03-058)”而提交的。心血管疾病是美国的头号死因。成年心肌细胞不增殖,因此当细胞永久性损伤时,心肌不能再生。我们最近从表达心脏特异性基因的小鼠ES细胞中分离出了几个纯的心肌细胞群。我们建议使用这些细胞作为组织工程构建的可再生来源。为了创建这些构建体,细胞将与胶原蛋白和纤连蛋白混合。使用定制设计的器械将结构暴露于多种机械或电刺激方案。 随着心脏的发育,心室心肌细胞的基因表达改变为终末分化的心肌细胞的基因表达。我们假设机械负荷和电刺激将诱导我们的基因选择的心肌细胞变得更好地组织和更高度分化。初步数据提供了使用HL-1心肌细胞或遗传选择的ES细胞创建构建体的概念证明。该数据还表明,可以使用该器械对结构施加机械载荷,并且机械载荷对结构及其细胞组分的形态有直接影响。拟议的研究定义了一个计划,使我们能够优化创建心脏组织工程构建体的条件,并研究机械负荷和电刺激对ES心肌细胞分化的影响。逆转录PCR将用于评估机械和电刺激对心脏基因表达的影响。将采用组织学、免疫组织化学和透射电子显微镜评估构建体的细胞形态。此外,将测试结构的机械性能,并与正常心肌进行比较。这项工作的意义在于,如果我们成功地实现了我们的目标,那么这种方法可以应用于人类ES细胞的使用,用于治疗性修复受伤的心肌或创建用于手术修复的人工心脏组织,或作为先天性出生缺陷重建手术的组织来源。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Embryonic stem cell-derived cardiomyocytes harbor a subpopulation of niche-forming Sca-1+ progenitor cells.
  • DOI:
    10.1007/s11010-010-0661-9
  • 发表时间:
    2011-03
  • 期刊:
  • 影响因子:
    4.3
  • 作者:
    Lam, May L.;Hashem, Sherin I.;Claycomb, William C.
  • 通讯作者:
    Claycomb, William C.
Store-operated calcium entry is present in HL-1 cardiomyocytes and contributes to resting calcium.
  • DOI:
    10.1016/j.bbrc.2011.10.133
  • 发表时间:
    2011-12-09
  • 期刊:
  • 影响因子:
    3.1
  • 作者:
    Touchberry, Chad D.;Elmore, Chris J.;Nguyen, Tien M.;Andresen, Jon J.;Zhao, Xiaoli;Orange, Matthew;Weisleder, Noah;Brotto, Marco;Claycomb, William C.;Wacker, Michael J.
  • 通讯作者:
    Wacker, Michael J.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WILLIAM C CLAYCOMB其他文献

WILLIAM C CLAYCOMB的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WILLIAM C CLAYCOMB', 18)}}的其他基金

Potential Use of ES Cells for Cardiac Tissue Engineering
ES 细胞在心脏组织工程中的潜在用途
  • 批准号:
    7195909
  • 财政年份:
    2007
  • 资助金额:
    $ 17.75万
  • 项目类别:
NOVEL GENE DISCOVERED IN THE HEART
在心脏中发现的新基因
  • 批准号:
    2750649
  • 财政年份:
    1999
  • 资助金额:
    $ 17.75万
  • 项目类别:
NOVEL GENE DISCOVERED IN THE HEART
在心脏中发现的新基因
  • 批准号:
    6184325
  • 财政年份:
    1999
  • 资助金额:
    $ 17.75万
  • 项目类别:
NOVEL GENE DISCOVERED IN THE HEART
在心脏中发现的新基因
  • 批准号:
    6389849
  • 财政年份:
    1999
  • 资助金额:
    $ 17.75万
  • 项目类别:
GROWTH OF THE HEART MUSCLE CELL
心肌细胞的生长
  • 批准号:
    3361584
  • 财政年份:
    1991
  • 资助金额:
    $ 17.75万
  • 项目类别:
GROWTH OF THE HEART MUSCLE CELL
心肌细胞的生长
  • 批准号:
    3361585
  • 财政年份:
    1991
  • 资助金额:
    $ 17.75万
  • 项目类别:
GROWTH OF THE HEART MUSCLE CELL
心肌细胞的生长
  • 批准号:
    2220860
  • 财政年份:
    1991
  • 资助金额:
    $ 17.75万
  • 项目类别:
HYPERTROPHY OF CULTURED SHR CARDIAC MYOCYTE
培养的 SHR 心肌细胞肥大
  • 批准号:
    3349685
  • 财政年份:
    1986
  • 资助金额:
    $ 17.75万
  • 项目类别:
HYPERTROPHY OF CULTURED SHR CARDIAC MYOCYTE
培养的 SHR 心肌细胞肥大
  • 批准号:
    3349683
  • 财政年份:
    1986
  • 资助金额:
    $ 17.75万
  • 项目类别:
HYPERTROPHY OF CULTURED SHR CARDIAC MYOCYTE
培养的 SHR 心肌细胞肥大
  • 批准号:
    3349684
  • 财政年份:
    1986
  • 资助金额:
    $ 17.75万
  • 项目类别:

相似海外基金

Phase I/II clinical trial of autologous T cell gene therapy to treat X-linked lymphoproliferative disease (XLP)
自体T细胞基因疗法治疗X连锁淋巴增殖性疾病(XLP)的I/II期临床试验
  • 批准号:
    MR/Y019458/1
  • 财政年份:
    2024
  • 资助金额:
    $ 17.75万
  • 项目类别:
    Research Grant
Fabrication and Evaluation of Poly(glycerol sebacate) based small diameter vascular graft as a potent substitution for autologous vessels
基于聚(甘油癸二酸酯)的小直径血管移植物作为自体血管有效替代品的制造和评估
  • 批准号:
    2897580
  • 财政年份:
    2023
  • 资助金额:
    $ 17.75万
  • 项目类别:
    Studentship
Autologous Bone Marrow Aspirate Concentrate for the Treatment of Osteonecrosis of the Femoral Head
自体骨髓抽吸浓缩液治疗股骨头坏死
  • 批准号:
    10658324
  • 财政年份:
    2023
  • 资助金额:
    $ 17.75万
  • 项目类别:
Identifying multimodal biomarkers for autologous serum tears in the treatment of chronic postoperative ocular pain
识别治疗慢性术后眼痛的自体血清泪液的多模式生物标志物
  • 批准号:
    10794761
  • 财政年份:
    2023
  • 资助金额:
    $ 17.75万
  • 项目类别:
SBIR Phase II: An Injectable Protein Matrix to Enhance the Stability of Autologous Fat Grafts
SBIR II 期:可注射蛋白质基质,增强自体脂肪移植物的稳定性
  • 批准号:
    2304430
  • 财政年份:
    2023
  • 资助金额:
    $ 17.75万
  • 项目类别:
    Cooperative Agreement
Application of Autologous Connective Tissue Sheets Created in Patients' Bodies to Pediatric Cardiac Valvuloplasty and Development of Dedicated Molds
患者体内自体结缔组织片在小儿心脏瓣膜成形术中的应用及专用模具的开发
  • 批准号:
    23K15543
  • 财政年份:
    2023
  • 资助金额:
    $ 17.75万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
MICA: Strategy for heart repair in Duchenne Muscular Dystrophy (DMD) using genetically engineered autologous Mesoangioblasts
MICA:利用基因工程自体中成血管细胞修复杜氏肌营养不良症 (DMD) 的心脏的策略
  • 批准号:
    MR/X00466X/1
  • 财政年份:
    2023
  • 资助金额:
    $ 17.75万
  • 项目类别:
    Fellowship
Planning a phase I study of minor salivary gland derived autologous MSCs for prevention of long-term radiation induced xerostomia
计划对小唾液腺来源的自体 MSC 进行 I 期研究,以预防长期辐射引起的口干症
  • 批准号:
    10720234
  • 财政年份:
    2023
  • 资助金额:
    $ 17.75万
  • 项目类别:
SBIR PHASE II, TOPIC 429: A NEW PARADIGM FOR AUTOLOGOUS AND ALLOGENEIC CELL THERAPY MANUFACTURING
SBIR 第二阶段,主题 429:自体和同种异体细胞治疗制造的新范式
  • 批准号:
    10976161
  • 财政年份:
    2023
  • 资助金额:
    $ 17.75万
  • 项目类别:
Evaluation of a therapeutic vaccination strategy with motif neoepitope peptide-pulsed autologous dendritic cells for non-small cell lung cancer patients harboring a charged HLA-B binding pocket.
使用基序新表位肽脉冲的自体树突状细胞对携带带电 HLA-B 结合袋的非小细胞肺癌患者的治疗性疫苗接种策略进行评估。
  • 批准号:
    10721983
  • 财政年份:
    2023
  • 资助金额:
    $ 17.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了